MEDICIS-Promed Final Conference

Session

Lessons learned from recent targeted radiotherapy treatments

30 Apr 2019, 09:30

Ettore Majorana Foundation (Erice)

Conveners

Lessons learned from recent targeted radiotherapy treatments

• Thierry Stora (CERN)
• John Olivier Prior

59. Small molecule inhibitors for tumor imaging and therapy

Prof. Uwe Haberkorn (University of Heidelberg)

30/04/2019, 09:30

Preclinical research and development of new radiopharmaceuticals

Invited

Technological advances in molecular biology and biotechnology are increasingly used for the development of new tumor targeting tracers. In oncology, major progress has recently been achieved with peptidic and small molecule compounds. This relies on the identification and validation of new target structures in close conjunction with the application of new techniques for the development of new...

60. Augmented and individualized radionuclide treatment (advances in PRRT / PRLT with a clinical focus on PSMA targeted radioligand therapy)

Prof. Samer Ezziddin (Saarland University Hospital, Homburg)

30/04/2019, 10:30

Preclinical research and development of new radiopharmaceuticals

Invited

With translation of new radioligands into clinical theragnostic practice, the therapeutic branch of nuclear medicine has gained fundamental momentum. The agonist-to-antagonist change in paradigm for different peptide receptor targeting systems is another current issue of major relevance. PSMA-targeted approaches are being discussed as role model treatment approach. Understanding the mechanism...

23. Role of THIK-1 in glioblastoma multiforme progression

Mrs Ioanna Prionisti (Unige, HUG)

30/04/2019, 11:00

Preclinical research and development of new radiopharmaceuticals

MEDICIS-Promed ESRs

Glioblastoma multiforme (GBM) [World Health Organization (WHO) grade IV astrocytoma] is the most malignant form of brain tumors, carrying a poor prognosis and high rate of recurrence. During the course of the disease, microglia and brain macrophages are both recruited by the tumor microenvironment via the release of several chemoattractants and contribute considerably in several aspects of...

48. High resolution preclinical and humanTotal body molecular imaging as companion tools for theranostics

Stefaan Vandenberghe (Ghent university, Belgium)

30/04/2019, 11:20

Preclinical research and development of new radiopharmaceuticals

Oral

Molecular imaging systems (PET, SPECT) have been improved over the last 20 years using small changes in either reconstruction methods, collimator or detector. The availability of highy sampled Silicon multipliers and advanced positioning algorithms (Maximum Likelihood, Deep learning,..) lead to scintillation detectors with sub mm transverse resolution (at competitive cost with older PMT based...

42. Determination of precision nuclear decay data for the decay of 153Gd

Robert Shearman (National Physical Laboratory)

30/04/2019, 11:40

Preclinical research and development of new radiopharmaceuticals

Oral

In the case of emerging radiopharmaceuticals, the accuracy and precision of the decay data of the radionuclide is crucially important. These data, particularly particle emission probabilities and the half-life, are necessary for the correct quantification of PET images and for dosimetry considerations of practitioners and patient alike.
Often precise nuclear data is determined through a...